Literature DB >> 1971163

Dexmedetomidine, a selective alpha 2-agonist, does not potentiate the cardiorespiratory depression of alfentanil in the rat.

S R Furst1, M B Weinger.   

Abstract

The authors examined the cardiovascular and respiratory effects of the highly selective alpha 2-adrenergic agonist dexmedetomidine, both alone and in combination with the synthetic opiate alfentanil. Spontaneously ventilating rats (n = 28) were pretreated with dexmedetomidine, 10 or 30 micrograms/kg; dexmedetomidine, 30 micrograms/kg in combination with the central-acting alpha 2-antagonist idazoxan, 10 mg/kg; or vehicle. Fifteen minutes later all rats received alfentanil, 500 micrograms/kg. Pretreatment with dexmedetomidine reduced heart rate in a dose-related fashion. Administration of alfentanil also caused a significant reduction in heart rate. However, following alfentanil, the dexmedetomidine-treated animals did not have significantly greater bradycardia than control animals. An increase in blood pressure was observed in those animals receiving the larger dose of dexmedetomidine, but this difference disappeared following injection of alfentanil. The addition of idazoxan to the pretreatment regimen prevented the changes seen with dexmedetomidine. Pretreatment with dexmedetomidine produced no significant changes in arterial pH or PCO2. In all groups, administration of alfentanil resulted in a decrease in arterial pH that ultimately became a mixed respiratory and metabolic acidosis. The acidosis promptly resolved following injection of naloxone (1 mg/kg). It appears that dexmedetomidine, at the doses given, has little or no effect on respiration. Dexmedetomidine decreases heart rate but does not add to bradycardia following alfentanil. There is a hypertensive effect seen at the higher dose of dexmedetomidine, but this effect disappears when the drug is given in conjunction with alfentanil. These data show that addition of the alpha 2-agonist dexmedetomidine will not worsen the cardiovascular and respiratory depression associated with high-dose opiates in the spontaneously ventilating rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971163     DOI: 10.1097/00000542-199005000-00019

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Dexmedetomidine: a novel sedative-analgesic agent.

Authors:  R Gertler; H C Brown; D H Mitchell; E N Silvius
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

2.  Assessment of dexmedetomidine effects on left ventricular function using pressure-volume loops in rats.

Authors:  Kyuho Lee; Hye Jeong Hwang; Ok Soo Kim; Young Jun Oh
Journal:  J Anesth       Date:  2016-11-05       Impact factor: 2.078

Review 3.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

4.  Dexmedetomidine Infusion to Control Agitation due to Anticholinergic Toxidromes in Adolescents, a Case Series.

Authors:  Samantha W Gee; Ada Lin; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 5.  Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia.

Authors:  H J Lemmens
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

6.  Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care.

Authors:  R M Venn; J Hell; R M Grounds
Journal:  Crit Care       Date:  2000-07-31       Impact factor: 9.097

7.  Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal.

Authors:  Riley J Lizotte; John A Kappes; Billie J Bartel; Katie M Hayes; Veronica L Lesselyoung
Journal:  Clin Pharmacol       Date:  2014-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.